Management ChangeAug 4, 2026, 08:56 AM
Johnson & Johnson EVP Jennifer Taubert to Retire; Tom Cavanaugh Appointed
AI Summary
Johnson & Johnson announced that Jennifer Taubert, Executive Vice President and Worldwide Chairman of Innovative Medicine, will retire effective September 1, 2026. Taubert had a distinguished 21-year career, during which she grew the Innovative Medicine business to over $60 billion in annual revenue. Tom Cavanaugh, currently Company Group Chairman, North America, Innovative Medicine, will succeed her and join the Executive Committee, ensuring a smooth leadership transition.
Key Highlights
- Jennifer Taubert will retire as Executive Vice President, Worldwide Chairman, Innovative Medicine.
- Her retirement is effective September 1, 2026, after a 21-year tenure.
- Tom Cavanaugh is appointed as her successor, effective September 1, 2026.
- Cavanaugh will also join the Johnson & Johnson Executive Committee.
- Taubert led the Innovative Medicine business to over $60 billion in annual revenue.
- Cavanaugh previously served as Company Group Chairman, North America, Innovative Medicine.
Price Impact
More from JNJ